Physician profile
Jake Oman
NPI 1730561143
$459.36
in general payments reported to CMS, 2019-2025
15 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.69 · 2022: $11.84 · 2024: $133 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $361.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $56.97 | 2024 | Auvelity |
| Exact Sciences Corporation | $55.31 | 2024-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $48.68 | 2025 | Ozempic, Rybelsus, Wegovy |
| Globus Medical, INC. | $42.35 | 2025 | Senza |
| Lilly USA, LLC | $36.57 | 2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $36.23 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.33 | 2019 | |
| Phathom Pharmaceuticals, INC. | $32.83 | 2024-2025 | Voquezna |
| Dexcom, INC. | $22.06 | 2024 | Dexcom G6 Transmitter |
| Scilex Pharmaceuticals INC. | $20.21 | 2019 | |
| Philips North America LLC | $18.50 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.13 | 2025 | Caplyta |
| Abbvie INC. | $14.70 | 2025 | |
| Merck Sharp & Dohme LLC | $12.65 | 2019 | |
| Terumo Medical Corporation | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jake Oman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.